Another matter considered during the Friday, January 30th session of the WHO Executive Board was the “Follow-up of the report on the Consultative Expert Working Group on Research Development-Financing and Coordination.” In addition to the general report on the CEWG, the EB also considered the Director General’s report on the CEWG “Health research and development demonstration projects.”
On Friday, January 30th, the WHO Executive Board discussed the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPA). The discussion covered several documents in relation to the GSPoA, including:
During Tuesday’s session of the WHO Executive Board, the board considered a proposal from Argentina on the table for a “Framework of Engagement with Non-state Actors.” Many states, both Board members and non-Executive Board member states, contributed to the discussion, citing the issue as a critical reform issue for the WHO. While a number of states took issue with some of the specifics of the draft proposal, for example that at current time all types of non-state actors were lumped together (i.e. Continue Reading
On Tuesday, 27 January 2015, Argentina, Brazil, India and South Africa tabled a draft decision to extend the mandate of the Global strategy and plan of action and public health, innovation and intellectual property (EB136/CONF.7) until 2022. We expect that this draft decision will be discussed on Thursday, 29 January 2015 under agenda item 10.5, Global strategy and plan of action on public health, innovation and intellectual property. Continue Reading
On Sunday January 25, 2015, the WHO Executive Board unanimously approved the resolution, “Ebola: Ending the current outbreak, strengthening global preparedness, and ensuring WHO capacity to prepare for and respond to future large-scale outbreaks and emergencies with health consequences.” Though unanimous in the end, negotiations for the resolution took 4 days, the Friday session lasting until 5:45am on Saturday morning.
At the WTO TRIPS Council in October 2014, Bangladesh, on behalf of the LDC Group, delivered the following intervention on “Extension of the Transition Period Under Article 66.1 of the TRIPS Agreement for Least-Developed Country Members for Certain Obligations with Respect to Pharmaceutical Products.” The current transition period incorporate two WTO decisions, TRIPS Council decision, IP/C/25 (Extension of the Transition Period under Article 66.1 of the TRIPS Agreement for Least-Developed Country Members for Certain Obligat Continue Reading